[1]

Guo Z, Wu D, Mao R, Yao Z, Wu Q, et al. 2025. Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021. Scientific Reports 15:7083

doi: 10.1038/s41598-025-91312-5
[2]

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, et al. 2023. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology 79:1542−1556

doi: 10.1016/j.jhep.2023.06.003
[3]

Chen H, Zhou Y, Hao H, Xiong J. 2024. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies. Chinese Journal of Natural Medicines 22:724−745

doi: 10.1016/s1875-5364(24)60690-4
[4]

Fabris L, Campello E, Cadamuro M, Simioni P. 2024. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): looking for the culprit. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1870:166763

doi: 10.1016/j.bbadis.2023.166763
[5]

Shi L, Chen H, Zhang Y, An D, Qin M, et al. 2025. SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis. The EMBO Journal 44:1442−1463

doi: 10.1038/s44318-025-00362-y
[6]

Xu X, Poulsen KL, Wu L, Liu S, Miyata T, et al. 2022. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 7:287

doi: 10.1038/s41392-022-01119-3
[7]

Rong L, Zou J, Ran W, Qi X, Chen Y, et al. 2022. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Frontiers in Endocrinology 13:1087260

doi: 10.3389/fendo.2022.1087260
[8]

Grander C, Grabherr F, Tilg H. 2023. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovascular Research 119:1787−1798

doi: 10.1093/cvr/cvad095
[9]

Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, et al. 2025. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis 400:119053

doi: 10.1016/j.atherosclerosis.2024.119053
[10]

Qin M, Shang L, Chen H, Shi L, Liu C, et al. 2026. SLC13A2-transported citrate remodels transcriptional regulation through protein acetylation to suppress tumor growth. Science Advances 12:eaec4368

doi: 10.1126/sciadv.aec4368
[11]

Karin M, Kim JY. 2025. Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. Pharmacological Reviews 77:100096

doi: 10.1016/j.pharmr.2025.100096
[12]

Sethi P, Mishra AK, Ghosh S, Singh KK, Sharma S, et al. 2025. Lipid metabolism-signaling crosstalk in metabolic disease and aging: mechanisms and therapeutic targets. Nutrients 17:3699

doi: 10.3390/nu17233699
[13]

Qian W, Tang H, Yao H. 2025. Lipidomics and temporal-spatial distribution of organelle lipid. Journal of Biological Methods 12:e99010049

doi: 10.14440/jbm.2025.0094
[14]

Seubnooch P, Montani M, Dufour JF, Masoodi M. 2024. Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis. Journal of Lipid Research 65:100599

doi: 10.1016/j.jlr.2024.100599
[15]

Fan YH, Zhang S, Wang Y, Wang H, Li H, et al. 2024. Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease. Frontiers in Endocrinology 15:1494560

doi: 10.3389/fendo.2024.1494560
[16]

Kumar P, Hassan M, Tacke F, Engelmann C. 2026. Mitochondria-endoplasmic reticulum contact sites in hepatocytic senescence. Cellular & Molecular Biology Letters 31:13

doi: 10.1186/s11658-025-00809-4
[17]

Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, et al. 2022. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. Journal of Hepatology 77:1136−1160

doi: 10.1016/j.jhep.2022.06.012
[18]

Venkatesan N, Doskey LC, Malhi H. 2023. The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. The American Journal of Pathology 193:1887−1899

doi: 10.1016/j.ajpath.2023.08.007
[19]

Liu Y, Wang Y, Zhou J, Li H, Liu C, et al. 2025. Restoring metabolic flexibility: targeting organelle interaction networks in the pathogenesis and therapy of MASLD. Frontiers in Cell and Developmental Biology 13:1718799

doi: 10.3389/fcell.2025.1718799
[20]

Duan L, Chang Y, Dai J, Lu H, Zhao W, et al. 2025. Lipid metabolism orchestrates liver regeneration: an integrated metabolic network. Journal of Translational Medicine 23:1115

doi: 10.1186/s12967-025-07232-5
[21]

Kim KH, Yoo BC. 2026. Decoding membrane lipids: analytical barriers and technological advances in modern lipidomics. International Journal of Molecular Sciences 27:1472

doi: 10.3390/ijms27031472
[22]

Tzouanas CN, Shay JES, Sherman MS, Rubin AJ, Mead BE, et al. 2026. Hepatic adaptation to chronic metabolic stress primes tumorigenesis. Cell 189:435−460.e28

doi: 10.1016/j.cell.2025.11.031
[23]

Sakuma I, Gaspar RC, Nasiri AR, Dufour S, Kahn M, et al. 2025. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis. Proceedings of the National Academy of Sciences 122:e2502978122

doi: 10.1073/pnas.2502978122
[24]

Uchiyama A, Kon K, Morinaga M, Fukada H, Yaginuma R, et al. 2025. Palmitic acid induces insulin resistance and oxidative stress-mediated cell injury through accumulation of lipid rafts in murine hepatocytes. Biochemical and Biophysical Research Communications 745:151242

doi: 10.1016/j.bbrc.2024.151242
[25]

Ogino N, Miyagawa K, Nagaoka K, Matsuura-Harada Y, Ogino S, et al. 2021. Role of HO-1 against saturated fatty acid-induced oxidative stress in hepatocytes. Nutrients 13:993

doi: 10.3390/nu13030993
[26]

Myojin Y, Kodama T, Takahashi R, Nagasawa H, Kondo Y, et al. 2026. Genome-wide CRISPR screen identifies ACSL3 as a regulator of lipotoxicity and progression of MASLD. Hepatology Communications 10:e0884

doi: 10.1097/hc9.0000000000000884
[27]

Garcia-Martinez I, Alen R, Pereira L, Povo-Retana A, Astudillo AM, et al. 2023. Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance. JHEP Reports 5:100756

doi: 10.1016/j.jhepr.2023.100756
[28]

Eynaudi A, Díaz-Castro F, Bórquez JC, Bravo-Sagua R, Parra V, et al. 2021. Differential effects of oleic and palmitic acids on lipid droplet-mitochondria interaction in the hepatic cell line HepG2. Frontiers in Nutrition 8:775382

doi: 10.3389/fnut.2021.775382
[29]

Zeng X, Zhu M, Liu X, Chen X, Yuan Y, et al. 2020. Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis. Nutrition & Metabolism 17:11

doi: 10.1186/s12986-020-0434-8
[30]

Kalyesubula M, Von Bank H, Davidson JW, Burhans MS, Becker MM, et al. 2025. Stearoyl-CoA desaturase 1 deficiency drives saturated lipid accumulation and increases liver and plasma acylcarnitines. Journal of Lipid Research 66:100824

doi: 10.1016/j.jlr.2025.100824
[31]

Chen X, Li L, Liu X, Luo R, Liao G, et al. 2018. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Life Sciences 203:291−304

doi: 10.1016/j.lfs.2018.04.022
[32]

Yu X, Huang C, Evers M, Liu J, Ting HJ, et al. 2025. Targeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH. Science Advances 11:eadx2681

doi: 10.1126/sciadv.adx2681
[33]

Zheng J, Gaspar RC, Sakuma I, Hubbard BT, Zhang D, et al. 2025. Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1, 2-DAGs-PKCε-insulin receptor kinaseT1150 pathway. Diabetologia 68:2906−2920

doi: 10.1007/s00125-025-06539-8
[34]

Alén R, Garcia-Martinez I, Cobo-Vuilleumier N, Fernández-Millán E, Gallardo-Villanueva P, et al. 2025. Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality. Diabetologia 68:1801−1822

doi: 10.1007/s00125-025-06445-z
[35]

Guerbette T, Rioux V, Bostoën M, Ciesielski V, Coppens-Exandier H, et al. 2024. Saturated fatty acids differently affect mitochondrial function and the intestinal epithelial barrier depending on their chain length in the in vitro model of IPEC-J2 enterocytes. Frontiers in Cell and Developmental Biology 12:1266842

doi: 10.3389/fcell.2024.1266842
[36]

Etxebeste-Mitxeltorena M, Flores-Romero H, Ramos-Inza S, Masiá E, Nenchova M, et al. 2025. Modulation of mitochondria-endoplasmic reticulum contacts (MERCs) by small molecules as a new strategy for restoring lipid metabolism in an amyotrophic lateral sclerosis model. Journal of Medicinal Chemistry 68:1179−1194

doi: 10.1021/acs.jmedchem.4c01368
[37]

Dadsena S, Bockelmann S, Mina JGM, Hassan DG, Korneev S, et al. 2019. Ceramides bind VDAC2 to trigger mitochondrial apoptosis. Nature Communications 10:1832

doi: 10.1038/s41467-019-09654-4
[38]

Lyu K, Zhang Y, Zhang D, Kahn M, Ter Horst KW, et al. 2020. A membrane-bound diacylglycerol species induces PKCϵ-mediated hepatic insulin resistance. Cell Metabolism 32:654−664.e5

doi: 10.1016/j.cmet.2020.08.001
[39]

Shamsan E, Almezgagi M, Gamah M, Khan N, Qasem A, et al. 2024. The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review. Frontiers in Medicine 11:1389329

doi: 10.3389/fmed.2024.1389329
[40]

Kano K, Aoki J, Hla T. 2022. Lysophospholipid mediators in health and disease. Annual Review of Pathology: Mechanisms of Disease 17:459−483

doi: 10.1146/annurev-pathol-050420-025929
[41]

Stofan M, Guo GL. 2020. Bile acids and FXR: novel targets for liver diseases. Frontiers in Medicine 7:544

doi: 10.3389/fmed.2020.00544
[42]

Wang H, Poulain S, Cao W, Arakawa H, Kim SH, et al. 2026. Palmitic acid induced the onset of lipotoxicity in a HepaSH-on-chip model with raised of H2O2 and IL-6, and altered p38/MAPK & JAK/STAT pathways. Toxicology 520:154345

doi: 10.1016/j.tox.2025.154345
[43]

Huang X, Yang G, Zhao L, Yuan H, Chen H, et al. 2021. Protein phosphatase 4 promotes hepatocyte lipoapoptosis by regulating RAC1/MLK3/JNK pathway. Oxidative Medicine and Cellular Longevity 2021:5550498

doi: 10.1155/2021/5550498
[44]

Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, et al. 2009. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. Journal of Biological Chemistry 284:26591−26602

doi: 10.1074/jbc.M109.022491
[45]

Sunami Y, Leithäuser F, Gul S, Fiedler K, Güldiken N, et al. 2012. Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation. Hepatology 56:1117−1128

doi: 10.1002/hep.25711
[46]

Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, et al. 2016. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 150:956−967

doi: 10.1053/j.gastro.2015.12.037
[47]

Leu SY, Tsang YL, Ho LC, Yang CC, Shao AN, et al. 2023. NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners. Journal of Endocrinology 257:e220184

doi: 10.1530/joe-22-0184
[48]

Sharma BR, Kanneganti TD. 2021. NLRP3 inflammasome in cancer and metabolic diseases. Nature Immunology 22:550−559

doi: 10.1038/s41590-021-00886-5
[49]

Kim DH, Choi G, Song EB, Lee H, Kim J, et al. 2025. Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. Cell Reports Medicine 6:102047

doi: 10.1016/j.xcrm.2025.102047
[50]

Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, et al. 2011. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. Journal of Biological Chemistry 286:39336−39348

doi: 10.1074/jbc.M111.280420
[51]

Tye H, Conos SA, Djajawi TM, Gottschalk TA, Abdoulkader N, et al. 2025. Divergent roles of RIPK3 and MLKL in high-fat diet-induced obesity and MAFLD in mice. Life Science Alliance 8:e202302446

doi: 10.26508/lsa.202302446
[52]

Hirsova P, Gores GJ. 2015. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology 1:17−27

doi: 10.1016/j.jcmgh.2014.11.005
[53]

Germain M, Milburn J, Duronio V. 2008. MCL-1 inhibits BAX in the absence of MCL-1/BAX interaction. Journal of Biological Chemistry 283:6384−6392

doi: 10.1074/jbc.M707762200
[54]

Kolczynska K, Loza-Valdes A, Hawro I, Sumara G. 2020. Diacylglycerol-evoked activation of PKC and PKD isoforms in regulation of glucose and lipid metabolism: a review. Lipids in Health and Disease 19:113

doi: 10.1186/s12944-020-01286-8
[55]

Zhang T, Zhou Y, Zhang Y, Wang DG, Lv QY, et al. 2024. Sesamin ameliorates nonalcoholic steatohepatitis through inhibiting hepatocyte pyroptosis in vivo and in vitro. Frontiers in Pharmacology 15:1347274

doi: 10.3389/fphar.2024.1347274
[56]

Lakshmipathi J, Alvarez-Perez JC, Rosselot C, Casinelli GP, Stamateris RE, et al. 2016. PKCζ is essential for pancreatic β-cell replication during insulin resistance by regulating mTOR and cyclin-D2. Diabetes 65:1283−1296

doi: 10.2337/db15-1398
[57]

Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, et al. 2023. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells. Biochemical and Biophysical Research Communications 642:192−200

doi: 10.1016/j.bbrc.2022.12.025
[58]

Dixon ED, Nardo AD, Claudel T, Trauner M. 2021. The role of lipid sensing nuclear receptors (PPARs and LXR) and metabolic lipases in obesity, diabetes and NAFLD. Genes 12:645

doi: 10.3390/genes12050645
[59]

Fougerat A, Bruse J, Polizzi A, Montagner A, Guillou H, et al. 2024. Lipid sensing by PPARα: role in controlling hepatocyte gene regulatory networks and the metabolic response to fasting. Progress in Lipid Research 96:101303

doi: 10.1016/j.plipres.2024.101303
[60]

Korbecki J, Bobiński R, Dutka M. 2019. Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors. Inflammation Research 68:443−458

doi: 10.1007/s00011-019-01231-1
[61]

Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, et al. 2021. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metabolism 33:1671−1684.e4

doi: 10.1016/j.cmet.2021.06.012
[62]

Adorini L, Trauner M. 2023. FXR agonists in NASH treatment. Journal of Hepatology 79:1317−1331

doi: 10.1016/j.jhep.2023.07.034
[63]

Ramírez CM, Torrecilla-Parra M, Pardo-Marqués V, de-Frutos MF, Pérez-García A, et al. 2021. Crosstalk between LXR and caveolin-1 signaling supports cholesterol efflux and anti-inflammatory pathways in macrophages. Frontiers in Endocrinology 12:635923

doi: 10.3389/fendo.2021.635923
[64]

Li X, Benegiamo G, Vijayakumar A, Sroda N, Kimura M, et al. 2026. An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. Nature Medicine 32:883−893

doi: 10.1038/s41591-025-04169-6
[65]

Arthur HU, Chen YY. 2025. PPARα modulation of macrophage polarization and inflammatory signaling in mimic periodontitis. Journal of Applied Oral Science 33:e20250338

doi: 10.1590/1678-7757-2025-0338
[66]

Lee SM, Muratalla J, Karimi S, Diaz-Ruiz A, Frutos MD, et al. 2023. Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice. Cellular and Molecular Life Sciences 80:39

doi: 10.1007/s00018-022-04629-z
[67]

Zhao S, Zhu Q, Lee WH, Funcke JB, Zhang Z, et al. 2025. The adiponectin-PPARγ axis in hepatic stellate cells regulates liver fibrosis. Cell Reports 44:115165

doi: 10.1016/j.celrep.2024.115165
[68]

Zhou J, Cui S, He Q, Guo Y, Pan X, et al. 2020. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nature Communications 11:240

doi: 10.1038/s41467-019-14138-6
[69]

Clark AT, Russo-Savage L, Ashton LA, Haghshenas N, Amselle NA, et al. 2025. A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis. Nature Communications 16:1102

doi: 10.1038/s41467-025-56565-8
[70]

Endo-Umeda K, Makishima M. 2019. Liver X receptors regulate cholesterol metabolism and immunity in hepatic nonparenchymal cells. International Journal of Molecular Sciences 20:5045

doi: 10.3390/ijms20205045
[71]

Zou Y, Tian L, Pei L, Hao J, Chen T, et al. 2025. SFAs facilitates ceramide's de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity. International Immunopharmacology 147:114020

doi: 10.1016/j.intimp.2025.114020
[72]

Liang H, Sathavarodom N, Colmenares C, Gelfond J, Espinoza SE, et al. 2022. Effect of acute TLR4 inhibition on insulin resistance in humans. Journal of Clinical Investigation 132:e162291

doi: 10.1172/jci162291
[73]

Song IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, Yang L, et al. 2018. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. International Journal of Cancer 142:81−91

doi: 10.1002/ijc.31029
[74]

Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 139:323−334.e7

doi: 10.1053/j.gastro.2010.03.052
[75]

Shepard CR. 2020. TLR9 in MAFLD and NASH: at the intersection of inflammation and metabolism. Frontiers in Endocrinology 11:613639

doi: 10.3389/fendo.2020.613639
[76]

Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, et al. 2011. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metabolism 14:21−32

doi: 10.1016/j.cmet.2011.06.002
[77]

Bo T, Gao L, Yao Z, Shao S, Wang X, et al. 2024. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metabolism 36:947−968

doi: 10.1016/j.cmet.2024.04.006
[78]

Zhou Y, Dai Y, Qin M, Li Y, Shi L, et al. 2026. FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis. Metabolism 175:156462

doi: 10.1016/j.metabol.2025.156462
[79]

Fonseca MC, França A, Florentino RM, Fonseca RC, Lima Filho ACM, et al. 2018. Cholesterol-enriched membrane microdomains are needed for insulin signaling and proliferation in hepatic cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 315:G80−G94

doi: 10.1152/ajpgi.00008.2018
[80]

Navyasree KV, Ramesh ST, Umasankar PK. 2023. Cholesterol regulates insulin-induced mTORC1 signaling. Journal of Cell Science 136:jcs261402

doi: 10.1242/jcs.261402
[81]

Wang G, Sun B, Liu H, Hu M, Xu H, et al. 2025. Interactions between lipid droplets and mitochondria in metabolic diseases. Lipids in Health and Disease 24:357

doi: 10.1186/s12944-025-02759-4
[82]

Ma X, Qian H, Chen A, Ni HM, Ding WX. 2021. Perspectives on mitochondria-ER and mitochondria-lipid droplet contact in hepatocytes and hepatic lipid metabolism. Cells 10:2273

doi: 10.3390/cells10092273
[83]

Liao J, Shao M, Zhou Z, Wang S, Lv Y, et al. 2025. Correlation of organelle interactions in the development of non-alcoholic fatty liver disease. Frontiers in Immunology 16:1567743

doi: 10.3389/fimmu.2025.1567743
[84]

Najt CP, Adhikari S, Heden TD, Cui W, Gansemer ER, et al. 2023. Organelle interactions compartmentalize hepatic fatty acid trafficking and metabolism. Cell Reports 42:112435

doi: 10.1016/j.celrep.2023.112435
[85]

Wang J, He W, Tsai PJ, Chen PH, Ye M, et al. 2020. Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease. Lipids in Health and Disease 19:72

doi: 10.1186/s12944-020-01210-0
[86]

Sassano ML, Felipe-Abrio B, Agostinis P. 2022. ER-mitochondria contact sites; a multifaceted factory for Ca2+ signaling and lipid transport. Frontiers in Cell and Developmental Biology 10:988014

doi: 10.3389/fcell.2022.988014
[87]

Basseri S, Austin RC. 2012. Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential. Biochemistry Research International 2012:841362

doi: 10.1155/2012/841362
[88]

Malhi H, Kaufman RJ. 2011. Endoplasmic reticulum stress in liver disease. Journal of Hepatology 54:795−809

doi: 10.1016/j.jhep.2010.11.005
[89]

Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, et al. 2018. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. Journal of Hepatology 69:927−947

doi: 10.1016/j.jhep.2018.06.008
[90]

Song MJ, Malhi H. 2019. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacology & Therapeutics 203:107401

doi: 10.1016/j.pharmthera.2019.107401
[91]

Chen C, Wu H, Ye H, Tortajada A, Rodríguez-Perales S, et al. 2021. Activation of the unfolded protein response (UPR) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease. Cancers 14:78

doi: 10.3390/cancers14010078
[92]

Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. 2022. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatology Communications 6:12−35

doi: 10.1002/hep4.1801
[93]

Ioannou GN, Subramanian S, Chait A, Haigh WG, Yeh MM, et al. 2017. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. Journal of Lipid Research 58:1067−1079

doi: 10.1194/jlr.M072454
[94]

Hu H, Tian M, Ding C, Yu S. 2018. The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Frontiers in Immunology 9:3083

doi: 10.3389/fimmu.2018.03083
[95]

Dasgupta D, Nakao Y, Mauer AS, Thompson JM, Sehrawat TS, et al. 2020. IRE1A stimulates hepatocyte-derived extracellular vesicles that promote inflammation in mice with steatohepatitis. Gastroenterology 159:1487−1503.e17

doi: 10.1053/j.gastro.2020.06.031
[96]

Sharma N, Arora S, Saurav S, Motiani RK. 2020. Pathophysiological significance of calcium signaling at Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs). Current Opinion in Physiology 17:234−242

doi: 10.1016/j.cophys.2020.08.012
[97]

Fernandes T, Domingues MR, Moreira PI, Pereira CF. 2023. A perspective on the link between mitochondria-associated membranes (MAMs) and lipid droplets metabolism in neurodegenerative diseases. Biology 12:414

doi: 10.3390/biology12030414
[98]

Bravo R, Vicencio JM, Parra V, Troncoso R, Munoz JP, et al. 2011. Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. Journal of Cell Science 124:2143−2152

doi: 10.1242/jcs.080762
[99]

Li Y, Tian X, Yu Q, Bao T, Dai C, et al. 2024. Alleviation of hepatic insulin resistance and steatosis with NMN via improving endoplasmic reticulum–mitochondria miscommunication in the liver of HFD mice. Biomedicine & Pharmacotherapy 175:116682

doi: 10.1016/j.biopha.2024.116682
[100]

Arruda AP, Pers BM, Parlakgül G, Güney E, Inouye K, et al. 2014. Chronic enrichment of hepatic endoplasmic reticulum–mitochondria contact leads to mitochondrial dysfunction in obesity. Nature Medicine 20:1427−1435

doi: 10.1038/nm.3735
[101]

Li YE, Sowers JR, Hetz C, Ren J. 2022. Cell death regulation by MAMs: from molecular mechanisms to therapeutic implications in cardiovascular diseases. Cell Death & Disease 13:504

doi: 10.1038/s41419-022-04942-2
[102]

Li F, Guan Z, Gao Y, Bai Y, Zhan X, et al. 2024. ER stress promotes mitochondrial calcium overload and activates the ROS/NLRP3 axis to mediate fatty liver ischemic injury. Hepatology Communications 8:e0399

doi: 10.1097/hc9.0000000000000399
[103]

Bui V, Santerre M, Shcherbik N, Sawaya BE. 2026. Mitochondria-associated membranes (MAMs): molecular organization, cellular functions, and their role in health and disease. FEBS Open Bio 16:11−24

doi: 10.1002/2211-5463.70121
[104]

Siskind LJ, Kolesnick RN, Colombini M. 2002. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. Journal of Biological Chemistry 277:26796−26803

doi: 10.1074/jbc.M200754200
[105]

Mansouri A, Gattolliat CH, Asselah T. 2018. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 155:629−647

doi: 10.1053/j.gastro.2018.06.083
[106]

Zhong X, Zhang Z, Shen H, Xiong Y, Shah YM, et al. 2021. Hepatic NF‐κB‐Inducing kinase and inhibitor of NF‐κB kinase subunit α promote liver oxidative stress, ferroptosis, and liver injury. Hepatology Communications 5:1704−1720

doi: 10.1002/hep4.1757
[107]

Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, et al. 2012. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36:401−414

doi: 10.1016/j.immuni.2012.01.009
[108]

Cheng H, Gang X, He G, Liu Y, Wang Y, et al. 2020. The molecular mechanisms underlying mitochondria-associated endoplasmic reticulum membrane-induced insulin resistance. Frontiers in Endocrinology 11:592129

doi: 10.3389/fendo.2020.592129
[109]

Beaulant A, Dia M, Pillot B, Chauvin MA, Ji-Cao J, et al. 2022. Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis. Journal of Hepatology 77:710−722

doi: 10.1016/j.jhep.2022.03.017
[110]

Obaseki E, Adebayo D, Bandyopadhyay S, Hariri H. 2024. Lipid droplets and fatty acid-induced lipotoxicity: in a nutshell. FEBS Letters 598:1207−1214

doi: 10.1002/1873-3468.14808
[111]

Schneiter R, Choudhary V. 2022. Seipin collaborates with the ER membrane to control the sites of lipid droplet formation. Current Opinion in Cell Biology 75:102070

doi: 10.1016/j.ceb.2022.02.004
[112]

Kimmel AR, Sztalryd C. 2016. The perilipins: major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage, mobilization, and systemic homeostasis. Annual Review of Nutrition 36:471−509

doi: 10.1146/annurev-nutr-071813-105410
[113]

Heeren J, Scheja L. 2021. Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular Metabolism 50:101238

doi: 10.1016/j.molmet.2021.101238
[114]

Bosma M, Dapito DH, Drosatos-Tampakaki Z, Huiping-Son N, Huang LS, et al. 2014. Sequestration of fatty acids in triglycerides prevents endoplasmic reticulum stress in an in vitro model of cardiomyocyte lipotoxicity. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1841:1648−1655

doi: 10.1016/j.bbalip.2014.09.012
[115]

Clare K, Dillon JF, Brennan PN. 2022. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD. Journal of Clinical and Translational Hepatology 10:939−946

doi: 10.14218/jcth.2022.00067
[116]

Fan H, Tan Y. 2024. Lipid droplet-mitochondria contacts in health and disease. International Journal of Molecular Sciences 25:6878

doi: 10.3390/ijms25136878
[117]

Danielli M, Perne L, Jarc Jovičić E, Petan T. 2023. Lipid droplets and polyunsaturated fatty acid trafficking: balancing life and death. Frontiers in Cell and Developmental Biology 11:1104725

doi: 10.3389/fcell.2023.1104725
[118]

Ericson E, Bergenholm L, Andréasson AC, Dix CI, Knöchel J, et al. 2022. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications 6:2689−2701

doi: 10.1002/hep4.2032
[119]

Jarc E, Petan T. 2019. Lipid droplets and the management of cellular stress. The Yale Journal of Biology and Medicine 92:435−452

doi: 10.1016/j.bbalip.2017.07.006
[120]

Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, et al. 2022. The ménage à trois of autophagy, lipid droplets and liver disease. Autophagy 18:50−72

doi: 10.1080/15548627.2021.1895658
[121]

Dong H, Czaja MJ. 2011. Regulation of lipid droplets by autophagy. Trends in Endocrinology & Metabolism 22:234−240

doi: 10.1016/j.tem.2011.02.003
[122]

Liu K, Czaja MJ. 2013. Regulation of lipid stores and metabolism by lipophagy. Cell Death & Differentiation 20:3−11

doi: 10.1038/cdd.2012.63
[123]

Zhang S, Peng X, Yang S, Li X, Huang M, et al. 2022. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. Cell Death & Disease 13:132

doi: 10.1038/s41419-022-04593-3
[124]

Kim KE, Shin HJ, Ju Y, Jung Y, An HS, et al. 2023. Intermittent fasting attenuates metabolic-dysfunction-associated steatohepatitis by enhancing the hepatic autophagy-lysosome pathway. Nutrients 15:4574

doi: 10.3390/nu15214574
[125]

Kaushik S, Cuervo AM. 2015. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nature Cell Biology 17:759−770

doi: 10.1038/ncb3166
[126]

Wang G, Chen L, Qin S, Zhang T, Yao J, et al. 2022. Mechanistic target of rapamycin complex 1: from a nutrient sensor to a key regulator of metabolism and health. Advances in Nutrition 13:1882−1900

doi: 10.1093/advances/nmac055
[127]

Yan S. 2022. Role of TFEB in autophagy and the pathogenesis of liver diseases. Biomolecules 12:672

doi: 10.3390/biom12050672
[128]

Trivedi PC, Bartlett JJ, Mercer A, Slade L, Surette M, et al. 2020. Loss of function of transcription factor EB remodels lipid metabolism and cell death pathways in the cardiomyocyte. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:165832

doi: 10.1016/j.bbadis.2020.165832
[129]

Zhao Q, Qu F, Jin Y. 2026. Lipophagy: a key regulator in oxidative stress and metabolic disorders. Genes & Diseases 13:102049

doi: 10.1016/j.gendis.2026.102049
[130]

Liu S, Yao S, Yang H, Liu S, Wang Y. 2023. Autophagy: regulator of cell death. Cell Death & Disease 14:648

doi: 10.1038/s41419-023-06154-8
[131]

Qin Y, Teker SS, La Cunza N, Tong Y, Theusch E, et al. 2026. Loss of TMEM55B modulates lipid metabolism through dysregulated lipophagy and mitochondrial function. Cell Death & Disease 17:26

doi: 10.1038/s41419-025-08210-x
[132]

Voronina MV, Frolova AS, Kolesova EP, Kuldyushev NA, Parodi A, et al. 2024. The intricate balance between life and death: ROS, cathepsins, and their interplay in cell death and autophagy. International Journal of Molecular Sciences 25:4087

doi: 10.3390/ijms25074087
[133]

Hernández-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, et al. 2012. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 142:938−946

doi: 10.1053/j.gastro.2011.12.044
[134]

Walker CL, Pomatto LCD, Tripathi DN, Davies KJA. 2018. Redox regulation of homeostasis and proteostasis in peroxisomes. Physiological Reviews 98:89−115

doi: 10.1152/physrev.00033.2016
[135]

Ding L, Sun W, Balaz M, He A, Klug M, et al. 2021. Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysis. Nature Metabolism 3:1648−1661

doi: 10.1038/s42255-021-00489-2
[136]

Pascual-Ahuir A, Manzanares-Estreder S, Proft M. 2017. Pro- and antioxidant functions of the peroxisome-mitochondria connection and its impact on aging and disease. Oxidative Medicine and Cellular Longevity 2017:9860841

doi: 10.1155/2017/9860841
[137]

Takashima S, Toyoshi K, Itoh T, Kajiwara N, Honda A, et al. 2017. Detection of unusual very-long-chain fatty acid and ether lipid derivatives in the fibroblasts and plasma of patients with peroxisomal diseases using liquid chromatography-mass spectrometry. Molecular Genetics and Metabolism 120:255−268

doi: 10.1016/j.ymgme.2016.12.013
[138]

Bezawork-Geleta A, Devereux CJ, Keenan SN, Lou J, Cho E, et al. 2025. Proximity proteomics reveals a mechanism of fatty acid transfer at lipid droplet-mitochondria- endoplasmic reticulum contact sites. Nature Communications 16:2135

doi: 10.1038/s41467-025-57405-5
[139]

Hu P, Li K, Peng X, Kan Y, Li H, et al. 2023. Nuclear receptor PPARα as a therapeutic target in diseases associated with lipid metabolism disorders. Nutrients 15:4772

doi: 10.3390/nu15224772
[140]

Weng H, Ji X, Naito Y, Endo K, Ma X, et al. 2013. Pex11α deficiency impairs peroxisome elongation and division and contributes to nonalcoholic fatty liver in mice. American Journal of Physiology. Endocrinology and Metabolism 304:E187−E196

doi: 10.1152/ajpendo.00425.2012
[141]

Zhong H, Liu C, Huang Z, Tan P, Chen H, et al. 2025. Crosstalk between hepatic stellate cells and hepatic macrophages in metabolic dysfunction-associated steatohepatitis. The American Journal of Pathology 195:1040−1056

doi: 10.1016/j.ajpath.2025.02.003
[142]

Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, et al. 2015. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cellular and Molecular Gastroenterology and Hepatology 1:646−663.e4

doi: 10.1016/j.jcmgh.2015.07.007
[143]

Bansal SK, Bansal MB. 2024. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Alimentary Pharmacology & Therapeutics 59:S10−S22

doi: 10.1111/apt.17930
[144]

Hirsova P, Ibrabim SH, Gores GJ, Malhi H. 2016. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. Journal of Lipid Research 57:1758−1770

doi: 10.1194/jlr.R066357
[145]

Ibrahim SH, Hirsova P, Gores GJ. 2018. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 67:963−972

doi: 10.1136/gutjnl-2017-315691
[146]

Carneiro AB, Iaciura BM, Nohara LL, Lopes CD, Veas EM, et al. 2013. Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. PLoS One 8:e76233

doi: 10.1371/journal.pone.0076233
[147]

Hall Z, Bond NJ, Ashmore T, Sanders F, Ament Z, et al. 2017. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. Hepatology 65:1165−1180

doi: 10.1002/hep.28953
[148]

Parthasarathy G, Hirsova P, Kostallari E, Sidhu GS, Ibrahim SH, et al. 2023. Extracellular vesicles in hepatobiliary health and disease. Comprehensive Physiology 13:4631−4658

doi: 10.1002/cphy.c210046
[149]

Nakao Y, Fukushima M, Mauer AS, Liao CY, Ferris A, et al. 2021. A comparative proteomic analysis of extracellular vesicles associated with lipotoxicity. Frontiers in Cell and Developmental Biology 9:735001

doi: 10.3389/fcell.2021.735001
[150]

Park WJ, Song JH, Kim GT, Park TS. 2020. Ceramide and sphingosine 1-phosphate in liver diseases. Molecules and Cells 43:419−430

doi: 10.14348/molcells.2020.0054
[151]

Peruzzi JA, Gunnels TF, Edelstein HI, Lu P, Baker D, et al. 2024. Enhancing extracellular vesicle cargo loading and functional delivery by engineering protein-lipid interactions. Nature Communications 15:5618

doi: 10.1038/s41467-024-49678-z
[152]

Zhao Y, Zhao MF, Jiang S, Wu J, Liu J, et al. 2020. Liver governs adipose remodelling via extracellular vesicles in response to lipid overload. Nature Communications 11:719

doi: 10.1038/s41467-020-14450-6
[153]

He Y, Rodrigues RM, Wang X, Seo W, Ma J, et al. 2021. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. Journal of Clinical Investigation 131:e141513

doi: 10.1172/jci141513
[154]

Ipsen DH, Tveden-Nyborg P. 2021. Extracellular vesicles as drivers of non-alcoholic fatty liver disease: small particles with big impact. Biomedicines 9:93

doi: 10.3390/biomedicines9010093
[155]

Lei Y, Liu M, Tao X. 2026. Extracellular vesicles: orchestrators of intrahepatic and systemic crosstalk in metabolic dysfunction-associated steatotic liver disease. Pharmaceutics 18:116

doi: 10.3390/pharmaceutics18010116
[156]

Tacke F. 2017. Targeting hepatic macrophages to treat liver diseases. Journal of Hepatology 66:1300−1312

doi: 10.1016/j.jhep.2017.02.026
[157]

Taru V, Szabo G, Mehal W, Reiberger T. 2024. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. Journal of Hepatology 81:895−910

doi: 10.1016/j.jhep.2024.06.016
[158]

Hammerich L, Tacke F. 2023. Hepatic inflammatory responses in liver fibrosis. Nature Reviews Gastroenterology & Hepatology 20:633−646

doi: 10.1038/s41575-023-00807-x
[159]

Dohnalkova E, Bayer RL, Guo Q, Bamidele AO, Kim Lee HS, et al. 2023. Rho-associated protein kinase 1 inhibition in hepatocytes attenuates nonalcoholic steatohepatitis. Hepatology Communications 7:e0171

doi: 10.1097/hc9.0000000000000171
[160]

Li X, Wang K, Sun Y, Wang Y, Wu J, et al. 2024. Cholesterol overload in macrophages drives metabolic dysfunction-associated steatohepatitis via inhibiting 7-dehydrocholesterol reductase in mice. Journal of Translational Medicine 22:1085

doi: 10.1186/s12967-024-05905-1
[161]

Iwata A, Maruyama J, Natsuki S, Nishiyama A, Tamura T, et al. 2024. Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice. Communications Biology 7:681

doi: 10.1038/s42003-024-06357-5
[162]

Saga A, Koseki M, Kanno K, Chang J, Higo T, et al. 2022. A dietary oxysterol, 7-ketocholesterol, exacerbates imiquimod-induced psoriasis-like dermatitis in steatohepatitic mice. International Journal of Molecular Sciences 23:15855

doi: 10.3390/ijms232415855
[163]

Akkız H, Gieseler RK, Canbay A. 2024. Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells. International Journal of Molecular Sciences 25:7873

doi: 10.3390/ijms25147873
[164]

Yan Y, Zeng J, Xing L, Li C. 2021. Extra- and intra-cellular mechanisms of hepatic stellate cell activation. Biomedicines 9:1014

doi: 10.3390/biomedicines9081014
[165]

Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, et al. 2014. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59:154−169

doi: 10.1002/hep.26604
[166]

Vos DY, van de Sluis B. 2021. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Molecular Metabolism 50:101146

doi: 10.1016/j.molmet.2020.101146
[167]

Li S, Yang F, Cheng F, Zhu L, Yan Y. 2024. Lipotoxic hepatocyte derived LIMA1 enriched small extracellular vesicles promote hepatic stellate cells activation via inhibiting mitophagy. Cellular & Molecular Biology Letters 29:82

doi: 10.1186/s11658-024-00596-4
[168]

Chen L, Brenner DA, Kisseleva T. 2019. Combatting fibrosis: exosome-based therapies in the regression of liver fibrosis. Hepatology Communications 3:180−192

doi: 10.1002/hep4.1290
[169]

Niu Q, Wang T, Wang Z, Wang F, Huang D, et al. 2022. Adipose-derived mesenchymal stem cell-secreted extracellular vesicles alleviate non-alcoholic fatty liver disease via delivering miR-223-3p. Adipocyte 11:572−587

doi: 10.1080/21623945.2022.2098583
[170]

Hou X, Yin S, Ren R, Liu S, Yong L, et al. 2021. Myeloid-cell-specific IL-6 signaling promotes microRNA-223-enriched exosome production to attenuate NAFLD-associated fibrosis. Hepatology 74:116−132

doi: 10.1002/hep.31658
[171]

Dai Q, Zhu D, Du X, Tan H, Chen Q. 2025. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicle in nonalcoholic fatty liver disease: a systematic review and meta-analysis of preclinical evidence. Lipids in Health and Disease 24:217

doi: 10.1186/s12944-025-02635-1
[172]

Xu J, Lu D, Huang X. 2026. Lipid metabolism and metabolites: emerging roles in systemic physiology and metabolic diseases. Journal of Genetics and Genomics 53:1143−1158

doi: 10.1016/j.jgg.2026.01.006
[173]

Bullón-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, et al. 2020. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Therapeutic Advances in Endocrinology and Metabolism 11:2042018820958298

doi: 10.1177/2042018820958298
[174]

Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, et al. 2022. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy 7:216

doi: 10.1038/s41392-022-01073-0
[175]

Kahn D, Macias E, Zarini S, Garfield A, Zemski Berry K, et al. 2022. Exploring visceral and subcutaneous adipose tissue secretomes in human obesity: implications for metabolic disease. Endocrinology 163:bqac140

doi: 10.1210/endocr/bqac140
[176]

Ali S, Vidal-Gómez X, Piquet M, Vergori L, Simard G, et al. 2025. Circulating extracellular vesicle-carried PTP1B and PP2A phosphatases as regulators of insulin resistance. Diabetologia 68:231−242

doi: 10.1007/s00125-024-06288-0
[177]

Dang SY, Leng Y, Wang ZX, Xiao X, Zhang X, et al. 2019. Exosomal transfer of obesity adipose tissue for decreased miR-141-3p mediate insulin resistance of hepatocytes. International Journal of Biological Sciences 15:351−368

doi: 10.7150/ijbs.28522
[178]

Malaguarnera M, Cauli O, Cabrera-Pastor A. 2025. Obesity and adipose-derived extracellular vesicles: implications for metabolic regulation and disease. Biomolecules 15:231

doi: 10.3390/biom15020231
[179]

Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, et al. 2024. P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. JCI Insight 9:e175623

doi: 10.1172/jci.insight.175623
[180]

Hu S, Cassim Bawa FN, Zhu Y, Pan X, Wang H, et al. 2024. Loss of adipose ATF3 promotes adipose tissue lipolysis and the development of MASH. Communications Biology 7:1300

doi: 10.1038/s42003-024-06915-x
[181]

Wang P, Zhang SY, Dong Y, Zeng G, Liu H, et al. 2024. Adipose ADM2 ameliorates NAFLD via promotion of ceramide catabolism. Acta Pharmaceutica Sinica B 14:4883−4898

doi: 10.1016/j.apsb.2024.09.010
[182]

Camacho-Morales A, Noriega LG, Sánchez-García A, Torre-Villalvazo I, Vázquez-Manjarrez N, et al. 2024. Plasma C24: 0 ceramide impairs adipose tissue remodeling and promotes liver steatosis and glucose imbalance in offspring of rats. Heliyon 10:e39206

doi: 10.1016/j.heliyon.2024.e39206
[183]

Hsiao YT, Yoshida Y, Okuda S, Abe M, Mizuno S, et al. 2024. PCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis. The EMBO Journal 43:5

doi: 10.1038/s44318-024-00196-0
[184]

Reghupaty SC, Coassolo L, Zhao M, Narasimhan RL, Patel A, et al. 2025. Genetic depletion of adipose-derived Isthmin-1 causes hepatic steatosis. Molecular Metabolism 98:102172

doi: 10.1016/j.molmet.2025.102172
[185]

Saha P, Hartmann P. 2025. Impact of gut microbiome on gut permeability in liver and gut diseases. Microorganisms 13:1188

doi: 10.3390/microorganisms13061188
[186]

Nakadate K, Saitoh H, Sakaguchi M, Miruno F, Muramatsu N, et al. 2025. Advances in understanding lipopolysaccharide-mediated hepatitis: mechanisms and pathological features. Current Issues in Molecular Biology 47:79

doi: 10.3390/cimb47020079
[187]

Chiang JYL, Ferrell JM. 2020. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. American Journal of Physiology. Gastrointestinal and Liver Physiology 318:G554−G573

doi: 10.1152/ajpgi.00223.2019
[188]

He J, Zhang P, Shen L, Niu L, Tan Y, et al. 2020. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. International Journal of Molecular Sciences 21:6356

doi: 10.3390/ijms21176356
[189]

Bahitham W, Banoun Y, Aljahdali M, Almuaiqly G, Bahshwan SM, et al. 2025. "Trust your gut" : exploring the connection between gut microbiome dysbiosis and the advancement of Metabolic Associated Steatosis Liver Disease (MASLD)/Metabolic Associated Steatohepatitis (MASH): a systematic review of animal and human studies. Frontiers in Nutrition 12:1637071

doi: 10.3389/fnut.2025.1637071
[190]

Tong L, Zhang S, Liu Q, Huang C, Hao H, et al. 2023. Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis. Science Advances 9:eade5041

doi: 10.1126/sciadv.ade5041
[191]

Kim JS, Song BJ, Cho YE. 2025. Pomegranate-derived exosome-like nanovesicles containing ellagic acid alleviate gut leakage and liver injury in MASLD. Food Science & Nutrition 13:e70088

doi: 10.1002/fsn3.70088
[192]

Niu B, Liu J, Zhou H, Chu W, Wu X, et al. 2025. ACT001 alleviates MASLD through gut microbiota–bile acid–FXR axis in mice. Annals of Medicine 57:2580773

doi: 10.1080/07853890.2025.2580773
[193]

Wang J, Gao J, Zhang Q, Lu J, Yang Y, et al. 2025. Ileal FXR knockdown ameliorates MASLD progression in rats via modulating bile acid metabolism mediated by gut microbiota. Journal of Gastroenterology and Hepatology 40:2091−2103

doi: 10.1111/jgh.17017
[194]

Xu S, Zhang Z, Zhou Z, Guo J. 2026. Immune determinants of MASLD progression: from immunometabolic reprogramming to fibrotic transformation. Biology 15:148

doi: 10.3390/biology15020148
[195]

Diehl KL, Vorac J, Hofmann K, Meiser P, Unterweger I, et al. 2020. Kupffer cells sense free fatty acids and regulate hepatic lipid metabolism in high-fat diet and inflammation. Cells 9:2258

doi: 10.3390/cells9102258
[196]

Holtmann TM, Inzaugarat ME, Knorr J, Geisler L, Schulz M, et al. 2021. Bile acids activate NLRP3 inflammasome, promoting murine liver inflammation or fibrosis in a cell type-specific manner. Cells 10:2618

doi: 10.3390/cells10102618
[197]

Pafili K, Roden M. 2021. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism 50:101122

doi: 10.1016/j.molmet.2020.101122
[198]

Wang GY, Zhang XY, Wang CJ, Guan YF. 2023. Emerging novel targets for nonalcoholic fatty liver disease treatment: evidence from recent basic studies. World Journal of Gastroenterology 29:75−95

doi: 10.3748/wjg.v29.i1.75
[199]

Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. 2022. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science 136:1347−1366

doi: 10.1042/CS20220572
[200]

Vitulo M, Gnodi E, Rosini G, Meneveri R, Giovannoni R, et al. 2023. Current therapeutical approaches targeting lipid metabolism in NAFLD. International Journal of Molecular Sciences 24:12748

doi: 10.3390/ijms241612748
[201]

Alkhouri N, Lawitz E, Noureddin M, DeFronzo R, Shulman GI. 2020. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 29:135−141

doi: 10.1080/13543784.2020.1668374
[202]

Calle RA, Amin NB, Carvajal-Gonzalez S, Ross TT, Bergman A, et al. 2021. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. Nature Medicine 27:1836−1848

doi: 10.1038/s41591-021-01489-1
[203]

Dandan M, Han J, Mann S, Kim R, Li K, et al. 2023. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate. Journal of Lipid Research 64:100339

doi: 10.1016/j.jlr.2023.100339
[204]

Bates J, Vijayakumar A, Ghoshal S, Marchand B, Yi S, et al. 2020. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. Journal of Hepatology 73:896−905

doi: 10.1016/j.jhep.2020.04.037
[205]

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, et al. 2021. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: fascinate-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology 161:1475−1486

doi: 10.1053/j.gastro.2021.07.025
[206]

Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, et al. 2021. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine 34:100797

doi: 10.1016/j.eclinm.2021.100797
[207]

Loomba R, Bedossa P, Grimmer K, Kemble G, Bruno Martins E, et al. 2024. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Gastroenterology & Hepatology 9:1090−1100

doi: 10.1016/S2468-1253(24)00246-2
[208]

Loomba R, Morgan E, Yousefi K, Li D, Geary R, et al. 2025. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): Results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 406:821−831

doi: 10.1016/s0140-6736(25)00979-1
[209]

Brisnovali NF, Haney C, Goedeke L. 2024. Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. Trends in Pharmacological Sciences 45:1081−1082

doi: 10.1016/j.tips.2024.08.009
[210]

Zhou J, Waskowicz LR, Lim A, Liao XH, Lian B, et al. 2019. A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type ia. Thyroid 29:1158−1167

doi: 10.1089/thy.2019.0007
[211]

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, et al. 2024. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. The New England Journal of Medicine 390:497−509

doi: 10.1056/NEJMoa2309000
[212]

Liu J, Yang F, Gao B, Yang L, Cao Y, et al. 2025. Resmetirom, the first FDA-approved drug for MASH: from drug discovery and action mechanisms to clinical trials. Archives of Pharmacal Research 48:1299−1313

doi: 10.1007/s12272-025-01574-w
[213]

Palavicini JP, Chavez-Velazquez A, Fourcaudot M, Tripathy D, Pan M, et al. 2021. The insulin-sensitizer pioglitazone remodels adipose tissue phospholipids in humans. Frontiers in Physiology 12:784391

doi: 10.3389/fphys.2021.784391
[214]

Moody AJ, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, et al. 2023. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 25:426−434

doi: 10.1111/dom.14885
[215]

Bradić I, Vujić N, Kuentzel KB, Habisch H, Pirchheim A, et al. 2024. Lanifibranor reduces inflammation and improves dyslipidemia in lysosomal acid lipase-deficient mice. Gastro Hep Advances 3:711−723

doi: 10.1016/j.gastha.2024.05.006
[216]

Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, et al. 2021. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. The New England Journal of Medicine 385:1547−1558

doi: 10.1056/NEJMoa2036205
[217]

Barb D, Kalavalapalli S, Godinez Leiva E, Bril F, Huot-Marchand P, et al. 2025. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of Hepatology 82:979−991

doi: 10.1016/j.jhep.2024.12.045
[218]

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, et al. 2019. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet 394:2184−2196

doi: 10.1016/s0140-6736(19)33041-7
[219]

Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, et al. 2021. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. Journal of Hepatology 75:25−33

doi: 10.1016/j.jhep.2021.01.047
[220]

Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, et al. 2017. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). Journal of Medicinal Chemistry 60:9960−9973

doi: 10.1021/acs.jmedchem.7b00907
[221]

Ratziu V, Sanyal A, Harrison SA, Wong VW, Francque S, et al. 2020. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology 72:892−905

doi: 10.1002/hep.31108
[222]

Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, et al. 2024. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: aurora phase III randomized study. Clinical Gastroenterology and Hepatology 22:124−134.e1

doi: 10.1016/j.cgh.2023.04.003
[223]

Gluchowski NL, Gabriel KR, Chitraju C, Bronson RT, Mejhert N, et al. 2019. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice. Hepatology 70:1972−1985

doi: 10.1002/hep.30765
[224]

Yang M, Li C, Sun L. 2021. Mitochondria-associated membranes (MAMs): a novel therapeutic target for treating metabolic syndrome. Current Medicinal Chemistry 28:1347−1362

doi: 10.2174/0929867327666200212100644
[225]

Hong H, Guo Z, Ge J, Li H. 2025. Mitochondria-associated endoplasmic reticulum membranes in health and diseases. MedComm 6:e70379

doi: 10.1002/mco2.70379
[226]

Jiang Z, Wu S, Zhou S, Zheng H, Bai Y, et al. 2025. Photobiomodulation mediates endoplasmic reticulum-mitochondria contact and ameliorates lipotoxicity in MASLD via Mfn2 upregulation. Journal of Photochemistry and Photobiology B: Biology 270:113209

doi: 10.1016/j.jphotobiol.2025.113209
[227]

Dong J, Chen L, Ye F, Tang J, Liu B, et al. 2024. Mic19 depletion impairs endoplasmic reticulum-mitochondrial contacts and mitochondrial lipid metabolism and triggers liver disease. Nature Communications 15:168

doi: 10.1038/s41467-023-44057-6
[228]

Li C, Li L, Yang M, Zeng L, Sun L. 2020. PACS-2: a key regulator of mitochondria-associated membranes (MAMs). Pharmacological Research 160:105080

doi: 10.1016/j.phrs.2020.105080
[229]

Lee D, Hong JH. 2023. Niemann-pick disease type C (NPDC) by mutation of NPC1 and NPC2: aberrant lysosomal cholesterol trafficking and oxidative stress. Antioxidants 12:2021

doi: 10.3390/antiox12122021
[230]

Guan D, Huang P, Liu X, Li Q, Zhang X, et al. 2025. Deficiency of myeloid NPC1 exacerbates liver injury and fibrosis by impairing macrophage efferocytosis. Journal of Advanced Research 72:213−227

doi: 10.1016/j.jare.2024.11.020
[231]

Lan Y, Qian B, Huang HY, Wang P, Li T, et al. 2022. Hepatocyte-derived prostaglandin E2-modulated macrophage M1-type polarization via mTOR-NPC1 axis-regulated cholesterol transport from lysosomes to the endoplasmic reticulum in hepatitis B virus x protein-related nonalcoholic steatohepatitis. International Journal of Molecular Sciences 23:11660

doi: 10.3390/ijms231911660
[232]

Lin JX, Xu CY, Wu XM, Che L, Li TY, et al. 2023. Rab7a-mTORC1 signaling-mediated cholesterol trafficking from the lysosome to mitochondria ameliorates hepatic lipotoxicity induced by aflatoxin B1 exposure. Chemosphere 320:138071

doi: 10.1016/j.chemosphere.2023.138071
[233]

Yamanashi Y, Takada T, Tanaka Y, Ogata Y, Toyoda Y, et al. 2022. Hepatic Niemann-Pick C1-Like 1 exacerbates non-alcoholic fatty liver disease by re-absorbing specific biliary oxysterols. Biomedicine & Pharmacotherapy 156:113877

doi: 10.1016/j.biopha.2022.113877
[234]

Xia D, Jiang X, Xie X, Zhou H, Yu D, et al. 2025. Identification of a novel NPC1L1 inhibitor from Danshen and its role in nonalcoholic fatty liver disease. International Journal of Molecular Sciences 26:2793

doi: 10.3390/ijms26062793
[235]

Cheng X, Liu N, Liu H, Huang N, Sun X, et al. 2020. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin. Bioorganic Chemistry 100:103914

doi: 10.1016/j.bioorg.2020.103914
[236]

Tan M, Mosaoa R, Graham GT, Kasprzyk-Pawelec A, Gadre S, et al. 2020. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death & Differentiation 27:2143−2157

doi: 10.1038/s41418-020-0491-6
[237]

Su M, Cao D, Wang Z, Duan Y, Huang Y. 2021. Fatty acid synthase inhibitor platensimycin intervenes the development of nonalcoholic fatty liver disease in a mouse model. Biomedicines 10:5

doi: 10.3390/biomedicines10010005
[238]

Sanjay KV, Vishwakarma S, Zope BR, Mane VS, Mohire S, et al. 2021. ATP citrate lyase inhibitor bempedoic acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. Current Research in Pharmacology and Drug Discovery 2:100051

doi: 10.1016/j.crphar.2021.100051
[239]

Marchianò S, Biagioli M, Morretta E, Di Giorgio C, Roselli R, et al. 2023. Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH. Scientific Reports 13:1602

doi: 10.1038/s41598-023-28647-4
[240]

Lin XF, Cui XN, Yang J, Jiang YF, Wei TJ, et al. 2024. SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. Acta Pharmacologica Sinica 45:2579−2597

doi: 10.1038/s41401-024-01389-3
[241]

Yasmin T, Rahman MM, Khan F, Kabir F, Nahar K, et al. 2021. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways. Biochemistry and Biophysics Reports 28:101168

doi: 10.1016/j.bbrep.2021.101168
[242]

Incorvaia D. 2025. Gilead culls Novo-partnered MASH candidate and 2 cancer assets. Biotech www.fiercebiotech.com/biotech/gilead-tidies-pipeline-culls-last-nash-program-and-2-cancer-assets
[243]

Wong VW, Amin NB, Takahashi H, Darekar A, Tacke F, et al. 2025. Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study. The Lancet Gastroenterology & Hepatology 10:924−940

doi: 10.1016/S2468-1253(25)00128-1
[244]

Saxena AR, Lyle SA, Khavandi K, Qiu R, Whitlock M, et al. 2023. A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, Obesity and Metabolism 25:992−1001

doi: 10.1111/dom.14946
[245]

Taylor NP. 2021. Pfizer dumps midphase NASH prospect, slew of early efforts in Q2 clear-out. Biotech www.fiercebiotech.com/biotech/pfizer-dumps-midphase-nash-prospect-quarterly-pipeline-cull
[246]

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, et al. 2016. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Annals of Internal Medicine 165:305−315

doi: 10.7326/m15-1774
[247]

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, et al. 2023. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77:1797−1835

doi: 10.1097/HEP.0000000000000323
[248]

ClinicalTrials.gov. 2021. A randomised, double-blind, placebo-controlled, multicentre, phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic Steatohepatitis (NASH) and Fibrosis stages F2 and F3. ClinicalTrials. gov NCT04849728. https://clinicaltrials.gov/study/NCT04849728
[249]

Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, et al. 2020. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72:58−71

doi: 10.1002/hep.31205
[250]

Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, et al. 2026. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology 83:1326−1340

doi: 10.1097/HEP.0000000000001608
[251]

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, et al. 2024. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. The New England Journal of Medicine 391:299−310

doi: 10.1056/NEJMoa2401943
[252]

ClinicalTrials.gov. 2025. A master protocol of multiple agents in adults with metabolic dysfunction-associated steatotic liver disease (SYNERGY-outcomes). ClinicalTrials. gov NCT07165028. https://clinicaltrials.gov/study/NCT07165028
[253]

Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, et al. 2021. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73:625−643

doi: 10.1002/hep.31622
[254]

Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, et al. 2022. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. Journal of Hepatology 77:607−618

doi: 10.1016/j.jhep.2022.04.003
[255]

Pianko S. 2021. A phase 2, randomized, double-blind, double-dummy, placebo-controlled study evaluating the safety and efficacy of semaglutide, and the fixed-dose combination of cilofexor and firsocostat, alone and in combination, in subjects with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). Medicine Monash Health RES-22-0000-633A. https://research.monash.edu/en/projects/a-phase-2-randomized-double-blind-double-dummy-placebo-controlled/
[256]

Cheung KS, Ng HY, Hui RWH, Lam LK, Mak LY, et al. 2024. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology 80:916−927

doi: 10.1097/hep.0000000000000855
[257]

Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, et al. 2020. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. Journal of Hepatology 73:26−39

doi: 10.1016/j.jhep.2020.02.027
[258]

Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, et al. 2020. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1−F3 fibrosis. Journal of Hepatology 72:816−827

doi: 10.1016/j.jhep.2019.11.024
[259]

Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, et al. 2020. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology 72:885−895

doi: 10.1016/j.jhep.2019.12.010
[260]

Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. 2024. Endpoints in NASH clinical trials: are we blind in one eye? Metabolites 14:40

doi: 10.3390/metabo14010040
[261]

Shah A, MacConell L, Liberman A, Di Bisceglie AM, Shapiro D. 2025. Challenges in histological endpoints for MASH therapies: an exercise in statistical modelling. Alimentary Pharmacology & Therapeutics 61:1489−1499

doi: 10.1111/apt.70023
[262]

Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos SA, Deng Y, et al. 2023. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study. Metabolism 147:155666

doi: 10.1016/j.metabol.2023.155666
[263]

Fichez J, Mouillot T, Vonghia L, Costentin C, Moreau C, et al. 2025. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Reports 7:101351

doi: 10.1016/j.jhepr.2025.101351
[264]

Anstee QM, Magnanensi J, Hajji Y, Caron A, Majd Z, et al. 2024. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH. JHEP Reports 6:101011

doi: 10.1016/j.jhepr.2024.101011
[265]

Mohan AA, Talwar P. 2025. MAM kinases: Physiological roles, related diseases, and therapeutic perspectives-a systematic review. Cellular & Molecular Biology Letters 30:35

doi: 10.1186/s11658-025-00714-w
[266]

Mendoza YP, Pastó R, Selicean SE, Gracia-Sancho J. 2026. Regression of fibrosis and portal hypertension in chronic liver disease: endothelial perspectives and clinical implications. Annals of Hepatology 31:102174

doi: 10.1016/j.aohep.2025.102174
[267]

Wang K, Zhang Y, Wang G, Hao H, Wang H. 2024. FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid. Medicinal Research Reviews 44:568−586

doi: 10.1002/med.21991
[268]

Pérez-Díaz AJ, Núñez-Sánchez MÁ, Ramos-Molina B. 2024. Revisiting liver metabolism through acetyl-CoA carboxylase inhibition. Trends in Endocrinology & Metabolism 35:563−565

doi: 10.1016/j.tem.2024.04.010
[269]

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, et al. 2021. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology 74:1809−1824

doi: 10.1002/hep.31843
[270]

Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, et al. 2024. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study. Clinical Gastroenterology and Hepatology 22:102−112.e9

doi: 10.1016/j.cgh.2023.04.011
[271]

Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, et al. 2017. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study. The Journal of Clinical Endocrinology and Metabolism 102:407−415

doi: 10.1210/jc.2016-2775
[272]

Anirvan P, Khan ZH, Bhuyan P, Dixit S, Dash R, et al. 2025. Gut microbiota and genetic polymorphisms appear to drive disease expression of nonalcoholic fatty liver disease in lean individuals. Journal of Clinical and Experimental Hepatology 15:102503

doi: 10.1016/j.jceh.2025.102503
[273]

Guo Y, Zhang N, Pei D. 2025. Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance. Frontiers in Microbiology 16:1645298

doi: 10.3389/fmicb.2025.1645298
[274]

Alkhouri N. 2025. Recent data from the ESSENCE trial on semaglutide in metabolic dysfunction-associated steatohepatitis. Gastroenterology & Hepatology 21:133−135
[275]

Francque SM. 2023. Towards precision medicine in non-alcoholic fatty liver disease. Reviews in Endocrine and Metabolic Disorders 24:885−899

doi: 10.1007/s11154-023-09820-6
[276]

Sheikh MY, Younus MF, Shergill A, Hasan MN. 2025. Diet and lifestyle interventions in metabolic dysfunction-associated fatty liver disease: a comprehensive review. International Journal of Molecular Sciences 26:9625

doi: 10.3390/ijms26199625
[277]

Kim S, Shin JH, Seo M, Pak ES, Jeon KH, et al. 2025. Pharmacological activation of AMP-activated protein kinase ameliorates liver fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model. International Journal of Biological Sciences 21:2957−2972

doi: 10.7150/ijbs.108731
[278]

Wang H, Liu X, Wang C, Yu S, Yang X, et al. 2025. Natural active botanical metabolites: targeting AMPK signaling pathway to treat metabolic dysfunction-associated fatty liver disease. Frontiers in Pharmacology 16:1611400

doi: 10.3389/fphar.2025.1611400
[279]

Sarkar S, Ghosh R. 2025. Unravelling lipid heterogeneity: advances in single-cell lipidomics in cellular metabolism and disease. BBA Advances 8:100169

doi: 10.1016/j.bbadva.2025.100169
[280]

Sookoian S, Rotman Y, Valenti L. 2024. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clinical Gastroenterology and Hepatology 22:2177−2187.e3

doi: 10.1016/j.cgh.2024.05.052
[281]

Carlsson B, Lindén D, Brolén G, Liljeblad M, Bjursell M, et al. 2020. Review article: The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 51:1305−1320

doi: 10.1111/apt.15738